Skip to main content

Table 3 Patient characteristics characterized according to whether the patients received tamoxifen (TAM) or toremifene (TOR) treatment

From: A comparison of survival outcomes and side effects of toremifene or tamoxifen therapy in premenopausal estrogen and progesterone receptor positive breast cancer patients: a retrospective cohort study

  TAM (n = 240) TOR (n = 212) P value
Age    0.552
18-34 34 26  
>35 206 186  
T    0.744
 1 147 137  
 2 84 67  
 3 9 8  
N    0.536
 0 142 136  
 1-3 61 52  
 4-9 27 19  
 ≥10 10 5  
AJCC Stage    0.616
 I 98 97  
 IIA 70 64  
 IIB 32 25  
 IIIA 30 21  
 IIIB 0 0  
 IIIC 10 5  
HER-2 status    0.359
 Positive 37 23  
 Negative 148 137  
 Unknown 55 52  
Grade    0.328
 I 51 37  
 II 141 120  
 III 47 52 0.530
 Unknown 1 3  
Risk of recurrence    0.313
 Low 11 15  
 Intermediate or 229 197  
 high    0.024
Local control 117 130  
 BCS + RT 90 57  
 Modified 33 25  
 Modified + RT    0.513
Chemotherapy 15 10  
 CMF 96 92  
 ET 62 42  
 FEC 43 45  
 TC 24 23  
 No chemotherapy    
  1. Differences between the two groups were evaluated using a χ2 test.